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ABSTRACT 
 
Objective: The purpose of this study was to assess the influence of three single 
nucleotide polymorphisms (SNP) previously associated with Alzheimer’s disease on 
specific domains of cognition, when controlling for Apolipoprotein E gene (APOE), in a 
sample of individuals with Alzheimer’s disease. Methods: The data were drawn from 
the Alzheimer’s Disease Neuroimaging Initiative database, a comprehensive, 
longitudinal database of controls, persons with mild cognitive impairment, and persons 
with mild Alzheimer’s disease. Each subject has a full neuropsychological assessment, 
neuroimaging, genetic sequencing, and physical evaluation. For the purposes of this 
study, individuals were selected based on the presence of the three SNPs of interest: 
CR1 (rs3818361_T), CLU (rs11136000_T), and PICALM (rs3851179_A). Each SNP 
was then measured against the available tests of the ADNI neuropsychological battery 
that measured immediate and long delay memory, semantic fluency, and confrontation 
naming. Results: Only the CR1 SNP (rs3818361_T) had significant findings. The 
presence of the CR1 SNP associated with lower performance on logical memory recall 
total score, AVLT immediate recall trials 2 and 4, AVLT delayed recall, and 
confrontation naming in the 12-month control group. Logical memory and AVLT delayed 
recall were also negatively associated with CR1 in the 12-month AD case group. 
Discussion: These results support previous findings that the CR1 SNP rs3818361_T is 
a risk factor for cognitive impairment in individuals with and without AD. Such findings 
	  iv 	  
can aid in the earlier detection of Alzheimer’s disease, risk for domain specific cognitive 
impairment, and novel targets for personalized pharmacotherapy. 
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CHAPTER ONE: 
INTRODUCTION 
Genetic markers are increasingly becoming an area of interest in the translational 
science community. This interest stems from the potential that genetic markers have for 
the early detection of a multitude of diseases and disorders; the use of that information 
in determining the pathophysiological etiologies; and the potential therapeutic 
intervention targets of serious, high impact diseases such as Alzheimer’s disease (AD) 
and other forms of dementia (Ramanan & Saykin, 2013). Currently, the greatest known 
genetic risk factor for sporadic late-onset (after age 65) AD is the APOE gene. APOE 
has three allelic variations, ε2, ε3, and ε4, with the ε4 variant conferring the greatest risk 
for development of AD. However, this polymorphism does not independently predict 
disease onset in all cases, and can be present in non-demented individuals 
(Bagyinszky, Youn, An, & Kim, 2014).  
Genome Wide Associations Studies (GWAS) have become an effective method 
of surveying entire genomes for common genetic variants within disease populations. 
From these studies, various single nucleotide polymorphisms (SNPs) have been 
identified as having significant association with disease onset and risk. However, these 
SNPs alone only contribute a small fraction of the overall risk for onset and must be 
assessed in concert with other variables, such as combined effects of other genetic 
variants and the influence of environmental factors (Ertekin-Taner, 2011).  Because the 
association of these SNPs with disease is garnered from massive, non-hypothesis 
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driven association studies, it is important to measure and assess phenotypes that may 
be affected by these polymorphisms and identify clinical risks that stem from these 
mutations (Ertekin-Taner, 2011). 
Support for Genes of Interest 
The European Alzheimer’s Disease Initiative (EADI) conducted a GWAS of 
537,029 SNPs in a sample of 2032 AD subjects, and 5328 controls and found 
significant negative association with the complement receptor type 1 (CR1) gene and a 
protective association for the clusterin (also referred to as apolipoprotein J; CLU) gene 
(Lambert et al., 2009). The Genetic and Environmental Risk in Alzheimer’s Disease 
(GERAD) consortium cross validated the findings of the EADI in a sample of 3941 
cases, 7848 controls, and analyzed 529,218 SNPs where they found significance for 
CLU as well as the phosphatidylinositol binding clathrin assembly protein (PICALM) 
gene (Harold et al., 2009). In a meta-analysis of EADI, GERAD, and the Cohort for 
Heart and Aging Research in Genomic Epidemiology (CHARGE; combined case 
sample of 8371 and control sample of 28,174) the attributable risk for Caucasians in 
CR1, CLU, and PICALM were approximated as 4%, 9%, and 9%, respectively (Seshadri 
et al., 2010). The data on associations of CR1, CLU, and PICALM with AD is variable in 
different ethnicities. In Chinese samples CR1 (Zhang et al., 2010) and CLU (Yu et al., 
2010) have been associated with AD. No association has been found in African 
Americans, Hispanics, or Arabs, but studies assessing these populations have been 
regarded as underpowered (Lambert & Amouyel, 2011). 
Through databases such as the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI), SNPs that have shown association with AD in other GWAS samples are now 
	  3 	  
being assessed in well controlled, longitudinal cohorts. Of relevance to this study are 
three SNPs in three genes shown to be present in AD cohorts: CR1, CLU, and PICALM 
(Harold, et al., 2009; Lambert, et al., 2009). These genes are of particular relevance, as 
they are known to associate with risk, or protection from, cognitive decline in carriers of 
APOE ε4, and are implicated in the clearance of Aβ deposits in the central nervous 
system. Each of these genes and their actions are reviewed below. 
CR1 
The gene CR1 is located on chromosome 1 and codes for the complement 
component (3b/4b) receptor 1, a transmembrane glycoprotein that is implicated in 
immune and glial-meditated inflammatory response and phagocytosis.  The protein CR1 
is a cell-surface receptor that has been found to potentially be involved in the clearance 
of amyloid and apoptotic cells (Wyss-Coray et al., 2002). CR1 expression in neuronal 
cells are low, and found most in the choroid plexus, while outside of the central nervous 
system CR1 is expressed most frequently in erythrocytes. Erythrocytes, via the CR1 
receptor, have been found to effectively sequester peripheral Aβ42 particles and assist 
in its clearance, a function that is found to be impaired in individuals with AD (Rogers et 
al., 2006). CR1 is also expressed in the Kolmer cells of the choroid plexus, linking it to 
CSF exchange with brain cells, and the introduction of leucocytes and CSF antigens, 
factors that can link AD with immune response to Aβ (Lambert & Amouyel, 2011).  
CR1 has been linked to AD through several GWAS studies where the presence 
of CR1 risk SNPs in APOE ε4 carriers resulted in a greater rate of decline in cognitive 
function in previously non-demented subjects secondary to increase amyloid deposition 
in brain cells (Hazrati et al., 2012). However, the influence of various CR1 alleles 
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confers different effects on amyloid load. Thambisetty and colleagues (Madhav 
Thambisetty et al., 2013) found carriers of CR1 SNP rs3818361_A, considered higher 
for disease risk, have lower measures of brain amyloid compared to non-carriers. This 
would seem to be in contradiction to the understood pathophysiology of AD, however as 
Thambisetty and colleagues note, modest amyloid deposition may be evidence of an 
adaptive immune response to the onset of disease. In a meta-analysis of current CR1 
risk allele association studies, Luo, et al (2014) tested known studies of CR1 predictive 
risk for AD onset. SNPs rs6656401 and rs3818361 were found to be highly significant 
predictors of AD susceptibility in Caucasians and Asian populations. Specifically of 
interest to this study, the T allele of rs3818361 conferred a greater risk for AD onset 
then the C allele (Luo et al., 2014).  
CLU 
The gene CLU is located on chromosome 8, codes for clusterin, and has been 
associated with the clearance of Aβ (particularly the highly toxic Aβ42), reduction of 
excessive inflammation and apoptosis, and clearance of neuronal debris (Pedraza et 
al., 2013). The CLU protein is expressed in great abundance in the central nervous 
system, and like APOE is an apolipoprotein (DeMattos et al., 2004). Expression levels 
of CLU in mRNA are greater in AD subjects compared to controls (M. Thambisetty et 
al., 2010). Associations have been assessed between concentrations of clusterin in 
blood plasma and CSF, and rates of cognitive decline in AD. Thambistetty and 
colleagues found that higher CSF clusterin concentrations correlated with greater 
endorhinal cortex and medial temporal lobe atrophy in AD, and to lesser extent, in 
patients with MCI. Higher blood plasma clusterin levels were also linked to lower Mini 
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Mental State Exam (MMSE) scores. Patients that had rapidly advancing cognitive 
impairment also exhibited higher clusterin concentration levels compared to slower 
advancing patients. There were no differences found between APOE ε4 carriers and 
non-carriers (Thambisetty, 2010). 
Allelic variations of rs11136000 confer differing levels of risk and functional 
consequences. The T allele has had split risk presentations. (Mengel-From et al., 2013) 
reported a greater rate of cognitive decline for a longitudinal Danish cohort T allele 
carriers, but subsequently found better cognitive composite score performance for T 
carriers then non-carriers in a separate Danish cohort, which they attributed to 
regression to the mean with increased age.  
PICALM 
The gene PICALM encodes for phosphatidylinositol binding clathrin assembly 
protein. It is primarily expressed in the endothelium of blood vessel walls, and like CR1 
is not found in high concentration in neurons. Thus PICALM has been hypothesized to 
participate in the transport Aβ across the blood brain barrier and into the peripheral 
blood stream (Lambert & Amouyel, 2011). PICALM expression association with AD is 
only found to be significant in white APOE ε4 carriers (Jun et al., 2010), and these 
results confirmed in another cohort by Hazrati and colleagues in (2012). The data on 
PICALM risk have been mixed, showing both protective and risky effects for the onset of 
AD. Meta-analysis of rs3851179 has shown risk for onset of AD in Caucasian 
populations, but not for African-American, Arab, or Hispanic groups (Jun, et al., 2010), 
however the association was reported to be moderated by a dose effect presence of 
APOE ε4 alleles. Of interest to this study, there are data to support the rs3851179 A 
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allele as a protective factor for the onset of AD. The rs3851179A isoform has been 
shown to exclude a critical exon necessary for coding of the PICALM protein, and 
comprises much of the association for reducing AD risk compared to other PICALM 
polymorphisms (Parikh, Fardo, & Estus, 2014). The conclusion of Parikh and colleagues 
for this protective influence is the expression of the rs3851179 A allele modestly 
increases the efficiency of brain microvasculature through more robust expression of 
the PICALM gene. Parikh, et al went further to say that previous mixed results of 
PICALM association with AD could be attributed to the differential expression of 
PICALM isoforms that were not measured in previous studies. It is also noted that the 
rs3851179 polymorphism is likely not directly responsible for this effect as it is upstream 
from the PICALM gene, but is rather in LD with a functional SNP not yet identified.  
Of interest to this study is the influence of these AD-associated SNPs on the cognitive 
profile of individuals with AD.  Specifically, are these polymorphisms associated with 
cognitive performance among individuals with AD? Perhaps these changes can be 
predictive and aid in early diagnosis and targeted treatment planning. 
 A better understanding of the influence that these genetic polymorphisms have 
on neuropsychological function may provide insight to more efficient detection methods 
for serious disorders of cognitive function and the course of progressive diseases such 
as AD. In this study, three AD-associated SNPs will be assessed for association with 
standardized measures of memory and language in a cohort of controls and individuals 
with AD. Results of the study will provide further information for the impact subtle 
genetic variations may have on the cognitive profile and course of AD.  
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CHAPTER TWO: 
METHODS
Data used in the preparation of this article were obtained from the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The National 
Institute on Aging (NIA), the National Institute of Biomedical Imaging and 
Bioengineering (NIBIB), the Food and Drug Administration (FDA), private 
pharmaceutical companies and non-profit organizations launched the ADNI in 2003, as 
a $60 million, 5- year public-private partnership. The primary goal of ADNI has been to 
test whether serial magnetic resonance imaging (MRI), positron emission tomography 
(PET), other biological markers, and clinical and neuropsychological assessment can be 
combined to measure the progression of mild cognitive impairment (MCI) and early 
Alzheimer’s disease (AD). Determination of sensitive and specific markers of very early 
AD progression is intended to aid researchers and clinicians to develop new treatments 
and monitor their effectiveness, as well as lessen the time and cost of clinical trials. 
Subject demographics 
The average age of all subjects was 81, with exception of the CR1 match 
baseline group, which was an average of 84. Average education ranged from 14.7 to 
15.7 years. Between 52% and 62% of subjects were male sex (summarized in Table 1). 
Three SNPs were chosen based on previous publications supporting their 
association with AD: CR1 (rs3818361_T), CLU (rs11136000_T), and PICALM 
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(rs3851179_A). Subjects were genotyped using the Human610-Quad BeadChip by 
Illumina to generate outputs of over 600,000 SNPs (Saykin et al., 2010).  
Case subjects were selected based on the presence of the SNPs of interest and 
a diagnosis of AD. The control group was ADNI subjects without AD with the SNPs of 
interest. Further, subjects were filtered based on the availability of neuropsychological 
tests that are clinically relevant to the AD cognitive profile. Subject scores were 
analyzed at baseline and at the 12-month visit.  
After filtering for the desired variables, there were 66, 106, and 95 control 
subjects at baseline for CR1, CLU, and PICALM, respectively. There were 77, 124, and 
110 subjects at 12-month testing. In the case group there were 274, 480, and 432 
subjects at baseline, and 249, 434, 390 at 12-month testing.  
Psychometrics 
Each SNP was measured against the available tests of the ADNI 
neuropsychological battery that measured immediate and long delay memory, semantic 
fluency, and confrontation naming; all domains relevant to diagnosis and measure of AD 
(Karantzoulis & Galvin, 2011). Measures used include Wechsler Memory Scales IV - 
Logical Memory subtest (Wechsler, 2009), the Auditory-Verbal Learning Test (AVLT; 
(Rey, 1941), Semantic Fluency tests (animals and vegetable categories), and the 
Boston Naming Test (Kaplan, Goodglass, & Weintraub, 2001).  
Wechsler Memory Scales – 4th Edition – Logical Memory  
 The WMS-IV LM subtests are a measure of immediate and long-delay memory 
for two stories of different content. The participant is read a story and asked to recall as 
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many details of the story as they can immediately after the story is read. This procedure 
is then repeated for a second trial. The participant is then read a different story following 
the same procedure. These trials function as an assessment of immediate memory 
recall. A delay of 15-20 minutes is then applied, during which the individual is 
administered other unrelated tasks. After the delay, the participant is then asked to 
recall as much of each story as they can without any cues. This is a measure of long-
term logical memory retrieval. The delay trial is then followed with a “True or False” 
forced choice recognition task for details of each story to assess awareness of the 
content of the original stories with cues (Wechsler, 2009). 
Auditory-Verbal Learning Test 
The AVLT is a measure of learning, and immediate and long-delay verbal 
memory, similar in structure to the WMS-IV LM subtests. Participants are read a list of 
15 phonemically and semantically dissimilar words and asked to recall as many of 
words as possible immediately after the list has been read to them. This procedure is 
repeated over the course five learning trials (Trials 1-5), over which the participant is 
anticipated to recall more words each subsequent trial. Upon completion of the five 
learning trials, the participant is then read a new list of 15 words (Trial B) that are 
semantically similar to the first list. Trial B is intended to serve as a distractor from the 
content of Trials 1-5. Upon completion of Trial B, the participant is then asked to recall 
as many words as possible from the first list (Trials 1-5) without the list being read to 
them again. This serves as a measure of working memory and short-term memory 
recall. The participant is then administered other tasks during a delay period of 30 
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minutes. After the delay, the participant is then asked to recall as many words as they 
can from the first list again (Trial 6). This is a measure of free recall long-term memory. 
A recognition trial is then administered, with forced choice “Yes or No” responses to 
assess the participant’s awareness of the lists previously read to them (Recognition). 
This measures long term storage of verbal information and specifically assesses the 
function of the hippocampus, a structure impaired by AD (Estévez-González, 
Kulisevsky, Boltes, Otermín, & García-Sánchez, 2003). 
Semantic Fluency Test 
 The semantic fluency test assesses a participant’s ability to verbally generate as 
many words as they can in 60 seconds that fit into a specific semantic category. This 
study used the standardized categories of Animals and Vegetables. Semantic fluency is 
a frequently used measure in the assessment of AD severity (Weakley & Schmitter-
Edgecombe, 2014); (Bertola et al., 2014).  
Boston Naming Test – 2nd Edition.  
 The BNT assesses confrontational naming, language-based memory retrieval, 
and knowledge for images of common items that are presented as individual line 
drawings. The BNT is an effective measure for the differential assessment of aphasia 
(Williams, Mack, & Henderson, 1989).  
Statistical Analysis 
Each SNP was tested for association with the chosen cognitive endophenotypes at 
baseline and 12-month visit. Multivariate linear regression was employed while 
controlling for sex, age, education, and APOE ε4 status
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CHAPTER THREE: 
RESULTS 
CR1 (rs3818361_T)  
Results for association of SNP rs3818361_T are summarized in Table 2. No 
significant findings were observed for the baseline measures for either the match or 
case groups. For the match group at 12-month testing, rs3818361_T associated with 
lower logical memory immediate recall total score (β = -1.2, p = 0.0023,), AVLT 
immediate recall Trial 2 (β = -0.5, p = 0.0305,) and Trial 4 (β = -0.6, p = 0.037), AVLT 
delayed recall total (β = -1.2, p= 0.023,), and confrontation naming spontaneous 
response total score (β = -1.7, p = 0.047).  
Other values that approached significance in the match group include lower 
scores on the AVLT immediate recall Trial 1 (β = -0.4, p = 0.066) and Trial 5 (β = -0.5, p 
= 0.0749).   
SNP rs3818361_T associated with lower logical memory immediate recall score 
(β = -0.6, p = 0.027) and AVLT delayed recall total score (β =  -0.8, p = 0.0016) in those 
with AD. 
CLU (rs11136000_T) 
Results for association of SNP rs11136000_T are summarized in Table 3. No 
significant associations were observed for rs11136000_T. Values that approached 
significance were observed in the 12-month case group: Trial 3 (β = 0.21, p = 0.101), 
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Trial 5 (β = 0.25, p = 0.08), and Trial 6 (β = 0.29, p = 0.08) of the AVLT, where better 
performance was associated with the presence of rs11136000_T in those with AD.   
PICALM (rs3851179_A) 
Results for association of SNP rs3851179_A are summarized in Table 4. No significant 
associations were measured for rs3851179_A. Measures that approached significance 
include higher Logical Memory immediate recall total score at baseline for the match 
group (β = 0.56, p = 0.09). Marginal significance was also observed for better 
performance on Trial B (β = 0.26, p = 0.08) of the AVLT for the match group at 12-
months.
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CHAPTER FOUR: 
DISCUSSION 
This study approached the hypothesis that genetic polymorphisms associated 
with risk for AD will associate with cognitive performance consistent with the cognitive 
profile of the disease. Logical memory, list-learning memory, and confrontation naming 
were all assessed in non-AD and AD subjects within the ADNI dataset.  
Based on these data, the presence of the CR1 SNP (rs3818361_T) resulted in 
lower measures of immediate recall memory for list learning and logical memory as well 
as lower confrontation naming scores in the match group at 12-month testing. The same 
reduced scores were found in the case group at one year follow up for immediate logical 
memory, and delayed list recall. This pattern indicates that the presence of 
rs3818361_T is a risk factor cognitive impairment in non-AD subjects, and to a lesser 
extent for subjects with AD.  
This study provides support for previous findings of Pedraza, et al (2013) for the 
influence of the rs3818361_T polymorphism of CR1 on cognitive function, in both 
cognitively normal older adults and those with AD, when controlling for the influence of 
APOE (Pedraza, et al., 2013). These findings, while supportive, may be underpowered 
based on a low sample size and influence from other known and unknown 
polymorphisms in linkage disequilibrium with CR1. Replication of this study would 
	  14 	  
benefit from a greater sample size and further investigation into differential influence of 
race as a variable.  
While the near significant findings for the CLU and PICALM SNPs are supported 
by literature indicating the protective effect of these polymorphisms, these values are 
underpowered and require further analysis in a larger sample to be validated. This is an 
often-cited concern in genetic association studies insufficient sample size (Naj et al., 
2011). However, as noted, CLU minor allele rs11136000_T is a known protective factor 
for AD risk, as it has been associated with increased CLU protein levels in the brain, 
and more efficient sequestration of Aβ (Ling, Bhongsatiern, Simpson, Fardo, & Estus, 
2012). But attempts to find cognitive endophenotypes for this marker have been mixed, 
often citing concerns for sample size and heterogeneity (Pedraza, et al., 2013).  
At the drafting of this manuscript, the CLU, CR1, and PICALM polymorphisms 
assessed were ranked in the top ten of the AlzGene database for most associated 
polymorphisms with AD (ranked 3rd, 5th, and 6th, respectively; Bertram, et al., 2007). 
These SNPs have had mixed results in GWAS-level studies for association with disease 
presence and phenotype, often modulated by noted factors such as sample size 
effecting power and ability to detect rare polymorphisms in the general population. As 
such, the so called “winner’s curse” may be at play with further replication warranted 
(Xiao & Boehnke, 2009). 
 Outside of the limitations set by sample size, replication of this study will benefit 
from more detailed neuropsychological assessment data, specifically assessment of 
cued recognition for the WMS-IV logical memory subtest and AVLT, as these sub 
scores aid in determining severity of hippocampus mediated cognitive abilities.  
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Another consideration for future analysis in larger samples would be grouped analysis 
of AD and non-AD individuals to increase variance across a continuum of cognitive 
scores, instead of parsing by diagnostic category. Previous groups (Chibnik et al., 2011; 
Bennett, De Jager, Leurgans, & Schneider, 2009) that have employed this method have 
showed greater association with cognitive endophenotypes then in diagnostically 
separate groups. This method can however cloud the true nature of an association and 
if the findings are tied to an independent cognitive process or AD mediated pathology.  
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Table	  1	  -­‐	  Subject	  Demographics	  
	  	  
	  
n	   Average	  Age	   Average	  Edu	   %	  Male	  
	  	   CR1	  rs3818361	   	  	   	  	   	  	  
Match	   Baseline	   66	   84	   14.7	   62%	  
12-­‐month	   77	   81	   14.7	   59%	  
Case	  
Baseline	   274	   81	   15.5	   58%	  
12-­‐month	   249	   81	   15.6	   57%	  
	  	  
	  
	  	   	  	   	  	   	  	  
	  	   CLU	  rs11136000	   	  	   	  	   	  	  
Match	  
Baseline	   106	   81	   15	   52%	  
12-­‐month	   124	   81	   15	   56%	  
Case	  
Baseline	   480	   81	   15.7	   58%	  
12-­‐month	   434	   81	   15.7	   59%	  
	  	  
	  
	  	   	  	   	  	   	  	  
	  	  
PICALM	  
rs3851179	   	  	   	  	   	  	  
Match	  
Baseline	   95	   81	   15	   59%	  
12-­‐month	   110	   81	   15	   60%	  
Case	  
Baseline	   432	   81	   15.6	   60%	  
12-­‐month	   390	   81	   15.7	   61%	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